乳がん治療薬の世界市場レポート 2025年

乳がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8％で582億3,000万米ドルに成長します。予測期間の成長は、高齢化人口の増加、新興市場、支持的な政策と政策、患者の支持と意識に起因しています。予測期間における主な動向としては、個別化医療、標的療法と免疫療法、臨床試験と医薬品パイプライン、併用療法、バイオマーカー主導型治療、遠隔医療と遠隔モニタリングなどが挙げられます。

乳がん治療薬市場の成長は、乳がん罹患率の上昇に後押しされています。乳がんは、乳房の細胞、典型的には乳管や小葉（乳汁分泌腺）から始まる疾患です。乳がん罹患率の増加は、平均寿命の延長、生殖パターンの変化、検出方法の強化、ホルモンの影響、肥満、ライフスタイルの選択、遺伝的素因、環境暴露などの要因に起因しています。乳がん治療薬は、がん細胞の増殖を標的にして抑制し、腫瘍を小さくし、がんの広がりを防ぎ、症状を管理し、生存率を向上させることによって、治療に重要な役割を果たします。例えば、2024年3月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、2022年には乳がんが世界全体で67万人の死亡を引き起こし、185カ国中157カ国の女性で最も多いがんであり、全症例の約半数は性別と年齢以外に特定の危険因子を持たない女性に発生したと報告しました。その結果、乳がんの有病率の増加が乳がん治療薬市場の拡大を牽引しています。

乳がんの有病率の上昇が乳がん治療薬市場の拡大を牽引しています。乳がんは、乳房の細胞から始まるがんの一種です。これらの細胞が制御不能に増殖し始め、しこりとして検出されたり画像検査で確認されたりする腫瘍が形成されることで発生します。乳がんの罹患率の増加は、人口の高齢化、ライフスタイルの変化、遺伝的要因、検出方法の進歩などの要因によるものです。乳がん治療薬は、がん細胞を標的とし、腫瘍の増殖を抑え、転移を予防し、個別化治療によって生存率を向上させることにより、治療を支援します。例えば、2022年9月、米国国立生物工学情報センター（NCBI）は、2040年までに新たに乳がんと診断される年間症例数が40％以上増加し、約300万人に達すると予測しました。乳がんの主な要因としては、遺伝、年齢、生活習慣などが挙げられ、先進国での有病率が高いです。乳がんと診断される人が増えるにつれて、乳がん治療薬に対する需要が高まり、乳がん治療薬市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界乳がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の乳がん治療薬市場：成長率分析
• 世界の乳がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の乳がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界乳がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乳がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 転移性乳がん
• トリプルネガティブ乳がん
• その他（乳管がん、浸潤性乳管がん、炎症性乳がん、妊娠中の乳がん、その他）
• 世界の乳がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局/ドラッグストア
• その他の流通チャネル
• 世界の乳がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外来
• 病院
• クリニック
• その他のエンドユーザー
• 世界の乳がん治療薬市場転移性乳がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン受容体陽性転移性乳がん
• HER2陽性転移性乳がん
• トリプルネガティブ転移性乳がん
• 世界の乳がん治療薬市場トリプルネガティブ乳がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法に基づく治療
• 免疫療法に基づく治療
• 標的療法
• 世界の乳がん治療薬市場、その他、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳管内がん（DCIS）
• 浸潤性乳管がん（IDC）
• 炎症性乳がん（IBC）
• 妊娠中の乳がん
• その他のサブタイプ（小葉がん、乳房パジェット病）

第7章 地域別・国別分析

• 世界の乳がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の乳がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乳がん治療薬市場：競合情勢
• 乳がん治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co. Inc.
• Genzyme Corporation
• Johnson & Johnson
• MacroGenics Inc.
• Celldex Therapeutics Inc.
• Onyx Pharmaceuticals Inc.
• BioNumerik Pharmaceuticals Inc.
• AbbVie Inc.
• Pfizer Inc.
• OncoGenex Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Bayer AG
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乳がん治療薬市場2029：新たな機会を提供する国
• 乳がん治療薬市場2029：新たな機会を提供するセグメント
• 乳がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Breast cancer drugs encompass a category of anti-cancer medications administered orally or intravenously to reach cancer cells throughout the body via the bloodstream. In cases where cancer has spread to the spinal fluid surrounding the brain and spinal cord (known as intrathecal chemotherapy), chemotherapy may be delivered directly to this region.

These drugs can be categorized into various types, including HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormonal receptors. Mitotic inhibitors, for instance, are designed to impede cell division, disrupting microtubules responsible for pulling apart chromosomes during cell division. Breast cancer drugs serve a range of applications, such as treating metastatic breast cancer and addressing different subtypes like triple-negative breast cancer. They are used across multiple healthcare sectors, including hospitals and clinics. The distribution of these drugs is facilitated through various channels, including ambulatory surgical centers, hospitals, clinics, retail pharmacies, and online platforms.

The breast cancer drugs market research report is one of a series of new reports from The Business Research Company that provides breast cancer drugs market statistics, including breast cancer drugs industry global market size, regional shares, competitors with a breast cancer drugs market share, detailed breast cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer drugs industry. This breast cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer drugs market size has grown strongly in recent years. It will grow from $39.66 billion in 2024 to $43.14 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing incidence of breast cancer, advancements in research and development, screening and early detection, evolving treatment guidelines, healthcare infrastructure development.

The breast cancer drugs market size is expected to see strong growth in the next few years. It will grow to $58.23 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising aging population, emerging markets, supportive policies and regulations, patient advocacy and awareness. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The growth of the breast cancer drug market is being fueled by the rising incidence of breast cancer, a disease that begins in the cells of the breast, typically in the milk ducts or lobules (milk-producing glands). The increase in breast cancer rates is attributed to factors such as longer life expectancy, shifts in reproductive patterns, enhanced detection methods, hormonal influences, obesity, lifestyle choices, genetic predisposition, and environmental exposures. Breast cancer drugs play a crucial role in treatment by targeting and inhibiting cancer cell growth, reducing tumor size, preventing the spread of cancer, managing symptoms, and improving survival rates. For example, in March 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2022, breast cancer caused 670,000 deaths globally, was the most common cancer in women across 157 out of 185 countries, and about half of all cases occurred in women with no specific risk factors other than sex and age. As a result, the increasing prevalence of breast cancer is driving the expansion of the breast cancer drug market.

The rising prevalence of breast cancer is driving the growth of the breast cancer drug market. Breast cancer is a type of cancer that begins in the cells of the breast. It occurs when these cells start to grow uncontrollably, forming a tumor that may be detected as a lump or seen on imaging tests. The growing incidence of breast cancer is attributed to factors such as aging populations, lifestyle changes, genetic factors, and advancements in detection methods. Breast cancer drugs aid in treatment by targeting cancer cells, reducing tumor growth, preventing metastasis, and improving survival rates through personalized therapies. For example, in September 2022, the National Center for Biotechnology Information (NCBI) in the US projected that by 2040, the annual number of newly diagnosed breast cancer cases would increase by over 40%, reaching around 3 million. The key factors contributing to breast cancer include heredity, age, and lifestyle, with a higher prevalence in developed countries. As more people are diagnosed with breast cancer, the demand for breast cancer drugs grows, fueling the expansion of the breast cancer drug market.

The growing adoption of targeted therapies is expected to drive the expansion of the breast cancer drugs market. Targeted therapies are treatments designed to specifically target certain molecules or pathways involved in the growth and spread of diseases like cancer. These therapies offer more effective and personalized treatment options, reduce side effects, improve survival rates, support research and development, and enhance patient awareness and regulatory approvals, all contributing to market growth. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported an increase in cancer diagnoses in the country, with the number rising from 160,570 cases in 2022 to 164,694 in 2023. This upward trend underscores the growing prevalence of cancer in Australia. Consequently, the increasing adoption of targeted therapies is fueling the growth of the breast cancer drugs market.

In the breast cancer drugs market, manufacturers are increasingly forging collaborative partnerships to drive business expansion. AstraZeneca, for instance, recently entered into a $6.9 billion partnership aimed at jointly developing the breast cancer drug trastuzumab deruxtecan. Under this agreement, both companies will share global development and commercialization costs for the drug. In a similar vein, Novartis joined forces with IBM Watson Health to create a solution that determines optimal drug combinations and sequences for improved patient outcomes.

Key players in the breast cancer drugs market are focusing on developing novel targeted therapies to gain a competitive advantage. Targeted therapies are specialized treatments designed to specifically target molecules or pathways involved in the growth and spread of diseases like breast cancer. In August 2022, the United States Food and Drug Administration (FDA) approved Enhertu as the first targeted therapy for HER2-low breast cancer, a subgroup that was previously categorized as HER2-negative. Clinical trials have shown that Enhertu can significantly enhance progression-free and overall survival rates for patients with HER2-low breast cancer. This approval marks a notable advancement in the customization of treatments for distinct breast cancer subtypes and aligns with the FDA's precision medicine commitment and the goals of the Cancer Moonshot program.

Manufacturers of breast cancer drugs must adhere to the regulatory oversight of various bodies, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the European Union. The EMA plays a crucial role in regulating the breast cancer drug market by granting licenses to drugs that have demonstrated both safety and clinical efficacy. These drugs undergo rigorous evaluation to assess their benefits and risks, including post-usage effects. Following approval from the EMA, a drug can be commercially distributed within the European Union. It's worth noting that conditional marketing authorization may be granted by the EMA, signifying approval, but this can be revoked if safety or effectiveness concerns arise.

Major companies operating in the breast cancer drugs market include F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC, Eli Lilly and Company Inc., Biocon Limited, Merck & Co. Inc., Genzyme Corporation, Johnson & Johnson, MacroGenics Inc., Celldex Therapeutics Inc., Onyx Pharmaceuticals Inc., BioNumerik Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., OncoGenex Pharmaceuticals Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Apthera Inc., Oncothyreon Inc., BiPar Sciences Inc., Puma Biotechnology Inc., Sanofi S.A., Genentech Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Accord Healthcare Limited, Alkem Laboratories Limited, Natco Pharma Limited, Fresenius Kabi AG, Lupin Limited, Glenmark Pharmaceuticals Limited

North America was the largest region in the breast cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the breast cancer drugs market during the forecast period. The regions covered in the breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the breast cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer drugs market consists of sales of Abemaciclib, Alpelisib, Anastrozole, and Aredia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Metastatic Breast Cancer; Triple Negative Breast Cancer; Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Other Distribution Channels
• 3) By End User: Ambulatory; Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Metastatic Breast Cancer: Hormone Receptor Positive Metastatic Breast Cancer; HER2 Positive Metastatic Breast Cancer; Triple Negative Metastatic Breast Cancer
• 2) By Triple Negative Breast Cancer: Chemotherapy-Based Treatments; Immunotherapy-Based Treatments; Targeted Therapy
• 3) By Others: Ductal Carcinoma In Situ (DCIS); Invasive Ductal Carcinoma (IDC); Inflammatory Breast Cancer (IBC); Breast Cancer During Pregnancy; Other Subtypes (Lobular Carcinoma, Paget's Disease of the Breast)
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; AstraZeneca PLC; Eli Lilly and Company Inc.; Biocon Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Drugs Market Characteristics

3. Breast Cancer Drugs Market Trends And Strategies

4. Breast Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Breast Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Breast Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Breast Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Breast Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Breast Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Breast Cancer Drugs Total Addressable Market (TAM)

6. Breast Cancer Drugs Market Segmentation

• 6.1. Global Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metastatic Breast Cancer
• Triple Negative Breast Cancer
• Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)
• 6.2. Global Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies/ Drug Stores
• Other Distribution Channels
• 6.3. Global Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ambulatory
• Hospitals
• Clinics
• Other End-Users
• 6.4. Global Breast Cancer Drugs Market, Sub-Segmentation Of Metastatic Breast Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Receptor Positive Metastatic Breast Cancer
• HER2 Positive Metastatic Breast Cancer
• Triple Negative Metastatic Breast Cancer
• 6.5. Global Breast Cancer Drugs Market, Sub-Segmentation Of Triple Negative Breast Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy-Based Treatments
• Immunotherapy-Based Treatments
• Targeted Therapy
• 6.6. Global Breast Cancer Drugs Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ductal Carcinoma In Situ (DCIS)
• Invasive Ductal Carcinoma (IDC)
• Inflammatory Breast Cancer (IBC)
• Breast Cancer During Pregnancy
• Other Subtypes (Lobular Carcinoma, Paget's Disease of the Breast)

7. Breast Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Breast Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Breast Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Drugs Market

• 8.1. Asia-Pacific Breast Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Drugs Market

• 9.1. China Breast Cancer Drugs Market Overview
• 9.2. China Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Drugs Market

• 10.1. India Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Drugs Market

• 11.1. Japan Breast Cancer Drugs Market Overview
• 11.2. Japan Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Drugs Market

• 12.1. Australia Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Drugs Market

• 13.1. Indonesia Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Drugs Market

• 14.1. South Korea Breast Cancer Drugs Market Overview
• 14.2. South Korea Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Drugs Market

• 15.1. Western Europe Breast Cancer Drugs Market Overview
• 15.2. Western Europe Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Drugs Market

• 16.1. UK Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Drugs Market

• 17.1. Germany Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Drugs Market

• 18.1. France Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Drugs Market

• 19.1. Italy Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Drugs Market

• 20.1. Spain Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Drugs Market

• 21.1. Eastern Europe Breast Cancer Drugs Market Overview
• 21.2. Eastern Europe Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Drugs Market

• 22.1. Russia Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Drugs Market

• 23.1. North America Breast Cancer Drugs Market Overview
• 23.2. North America Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Drugs Market

• 24.1. USA Breast Cancer Drugs Market Overview
• 24.2. USA Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Drugs Market

• 25.1. Canada Breast Cancer Drugs Market Overview
• 25.2. Canada Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Drugs Market

• 26.1. South America Breast Cancer Drugs Market Overview
• 26.2. South America Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Drugs Market

• 27.1. Brazil Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Drugs Market

• 28.1. Middle East Breast Cancer Drugs Market Overview
• 28.2. Middle East Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Drugs Market

• 29.1. Africa Breast Cancer Drugs Market Overview
• 29.2. Africa Breast Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Breast Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Breast Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Breast Cancer Drugs Market Competitive Landscape
• 30.2. Breast Cancer Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Merck & Co. Inc.
• 31.2. Genzyme Corporation
• 31.3. Johnson & Johnson
• 31.4. MacroGenics Inc.
• 31.5. Celldex Therapeutics Inc.
• 31.6. Onyx Pharmaceuticals Inc.
• 31.7. BioNumerik Pharmaceuticals Inc.
• 31.8. AbbVie Inc.
• 31.9. Pfizer Inc.
• 31.10. OncoGenex Pharmaceuticals Inc.
• 31.11. Astellas Pharma Inc.
• 31.12. Bristol-Myers Squibb Company
• 31.13. Bayer AG
• 31.14. GlaxoSmithKline plc
• 31.15. Teva Pharmaceutical Industries Ltd.

32. Global Breast Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Drugs Market

34. Recent Developments In The Breast Cancer Drugs Market

35. Breast Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Breast Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Breast Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Breast Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer